Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck

British Journal of Cancer

Volumn 87, Issue 12, 2002, Pages 1390-1395

  Fouret, Pierre ^a   Temam, S ^b   Charlotte, F ^a   Lacau St Guily, J ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL TENON   (France)

Author keywords

Fluorouracil; Induction; Platin

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN BCL 2;

ADULT; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG RESPONSE; EXON; FEMALE; GENE; GENE SEQUENCE; HEAD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NECK; P53 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA, NEOPLASM; FEMALE; FLUOROURACIL; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037011673     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600648     Document Type: Article

References (30)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2: 811-814
2. Anwar K, Nakakuki K, Imai H, Naiki H, Inuzuka M (1993) Over-expression of p53 protein in human laryngeal carcinoma. Int J Cancer 53:952-956
3. Baretton GB, Diebold J, Christoforis G, Vogt M, Muller C, Dopfer K, Schneiderbanger K, Schmidt M, Lohrs U (1996) Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77: 255-264
4. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1: 1029-1034
5. Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier AM, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-Puig P (2000) p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 18: 1465-1473
6. Chresta CM, Masters JR, Hickman JA (1996) Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56: 1834-1841
7. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
8. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, Lohrs U (1996) bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 105: 341-349
9. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G (1995) Bcl-2 protein: A prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 71: 1003-1007
10. Gallo O, Boddi V, Calzolari A, Simonetti L, Trovati M, Bianchi S (1996) bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 2: 261-267
11. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, Boracchi P, Guglielmi RB, Pezzella F (1995) Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1: 1375-1383
12. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87: 265-272
13. Homma A, Furuta Y, Oridate N, Nakano Y, Kohashi G, Yagi K, Nagahashi T, Fukuda S, Inoue K, Inuyama Y (1999) Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res 5: 801-806
14. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428
15. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337: 529-534
16. Joensuu H, Pylkkanen L, Toikkanen S (1994) Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191-1198
17. Koch WM, Brennan JA, Zahurak M, Goodman SN, Westra WH, Schwab D, Yoo GH, Lee DJ, Forastiere AA, Sidransky D (1996) p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 1580-1586
18. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21: 485-495
19. Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967
20. Lu QL, Elia G, Lucas S, Thomas JA (1993) Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma, Int J Cancer 53: 29-35
21. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619
22. Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM (1999) Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 85: 164-170
23. Pezzella F, Tse AG, Cordell JL, Pulford KA, Gatter KC, Mason DY (1990) Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 137: 225-232
24. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694
25. Ribeiro Jr U, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC (1998) p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83: 7-18
26. Schmitt CA, Rosenthal CT, Lowe SW (2000) Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6: 1029-1035
27. Shimizu S, Narita M, Tsujimoto Y (1999) Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487
28. Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL, Fouret P (2000) p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18: 385-394
29. Tsujimoto Y, Cossman J, Jaffe E, Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443
30. Wilson GD, Grover R, Richman PI, Daley FM, Saunders MI, Dische S (1996) Bcl-2 expression correlates with favourable outcome in head and neck cancer treated by accelerated radiotherapy. Anticancer Res 16: 2403-2408